BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duchow A, Bellmann-strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 2021;11:49-59. [DOI: 10.2217/nmt-2020-0046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Heydari AH, Heydari S, Heidari ME. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther 2023;37:239-44. [PMID: 34826037 DOI: 10.1007/s10557-021-07294-9] [Reference Citation Analysis]
2 Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev 2023;22:103312. [PMID: 36924922 DOI: 10.1016/j.autrev.2023.103312] [Reference Citation Analysis]
3 Kohle F, Dalakas MC, Lehmann HC. Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? Ther Adv Neurol Disord 2023;16:17562864221137129. [PMID: 36620728 DOI: 10.1177/17562864221137129] [Reference Citation Analysis]
4 Vishnevetsky A, Kaplan TB, Levy M. Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch. Expert Opinion on Biological Therapy 2022. [DOI: 10.1080/14712598.2022.2145879] [Reference Citation Analysis]
5 Jiao L, Guo S. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.966766] [Reference Citation Analysis]
6 Shi M, Chu F, Jin T, Zhu J. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD. CNS Neurosci Ther 2022;28:981-91. [PMID: 35426485 DOI: 10.1111/cns.13836] [Reference Citation Analysis]
7 Luitel P, Ghimire A, Upadhyay D, Ojha R. Efficacy of monoclonal antibodies in neuromyelitis optica: An updated systematic review with meta‐analysis. Clinical & Exp Neuroim 2022. [DOI: 10.1111/cen3.12695] [Reference Citation Analysis]
8 Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord 2021;14:17562864211035542. [PMID: 34457039 DOI: 10.1177/17562864211035542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
9 Liu C, Shi M, Zhu M, Chu F, Jin T, Zhu J. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmun Rev 2021;:102921. [PMID: 34384938 DOI: 10.1016/j.autrev.2021.102921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chamlagain R, Shah S, Gaire S, Paudel AK, Dahal K, kandel B, Dhital R, Paudel BS, Dhakal S, Basnet M. Systematic Review and Meta-analysis of Eculizumab, Inebilizumab, Tocilizumab, and Satralizumab for Neuromyelitis Optica.. [DOI: 10.1101/2021.07.22.21261005] [Reference Citation Analysis]
11 Baker D, Hadjicharalambous C, Gnanapavan S, Giovannoni G. Can rheumatologists stop causing demyelinating disease? Mult Scler Relat Disord 2021;53:103057. [PMID: 34126373 DOI: 10.1016/j.msard.2021.103057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]